ES2103966T3 - Uso de una timosina en el tratamiento de hepatitis c. - Google Patents

Uso de una timosina en el tratamiento de hepatitis c.

Info

Publication number
ES2103966T3
ES2103966T3 ES92919977T ES92919977T ES2103966T3 ES 2103966 T3 ES2103966 T3 ES 2103966T3 ES 92919977 T ES92919977 T ES 92919977T ES 92919977 T ES92919977 T ES 92919977T ES 2103966 T3 ES2103966 T3 ES 2103966T3
Authority
ES
Spain
Prior art keywords
treatment
hepatitis
thymosine
thymosines
alone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92919977T
Other languages
English (en)
Spanish (es)
Inventor
Milton Mutchnick
Paul Chretian
Kenneth E Sherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Alpha 1 Biomedicals Inc
United States Department of the Army
Original Assignee
Wayne State University
Alpha 1 Biomedicals Inc
United States Department of the Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University, Alpha 1 Biomedicals Inc, United States Department of the Army filed Critical Wayne State University
Application granted granted Critical
Publication of ES2103966T3 publication Critical patent/ES2103966T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Beans For Foods Or Fodder (AREA)
ES92919977T 1991-09-13 1992-09-08 Uso de una timosina en el tratamiento de hepatitis c. Expired - Lifetime ES2103966T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75954491A 1991-09-13 1991-09-13

Publications (1)

Publication Number Publication Date
ES2103966T3 true ES2103966T3 (es) 1997-10-01

Family

ID=25056052

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92919977T Expired - Lifetime ES2103966T3 (es) 1991-09-13 1992-09-08 Uso de una timosina en el tratamiento de hepatitis c.

Country Status (23)

Country Link
US (3) US6001799A (esLanguage)
EP (1) EP0603305B1 (esLanguage)
JP (1) JP3228512B2 (esLanguage)
KR (1) KR100254082B1 (esLanguage)
AT (1) ATE152914T1 (esLanguage)
AU (1) AU667327B2 (esLanguage)
CA (1) CA2119006C (esLanguage)
CZ (1) CZ286827B6 (esLanguage)
DE (1) DE69219782T2 (esLanguage)
DK (1) DK0603305T3 (esLanguage)
ES (1) ES2103966T3 (esLanguage)
FI (1) FI107879B (esLanguage)
GR (1) GR3024025T3 (esLanguage)
HK (1) HK1021687A1 (esLanguage)
HU (1) HU221006B1 (esLanguage)
MX (1) MX9205240A (esLanguage)
NO (1) NO941310L (esLanguage)
RO (1) RO111991B1 (esLanguage)
RU (1) RU2104010C1 (esLanguage)
SG (1) SG64897A1 (esLanguage)
TW (1) TW224053B (esLanguage)
WO (1) WO1993005806A1 (esLanguage)
ZA (1) ZA926964B (esLanguage)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007132037A1 (es) * 2006-05-10 2007-11-22 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (esLanguage) * 1991-09-13 1994-05-21 Paul B Chretien
WO1995011688A1 (en) * 1992-02-06 1995-05-04 Sciclone Pharmaceuticals Method for treating hepatitis b carriers with minimal disease
WO1994001125A1 (en) * 1992-07-13 1994-01-20 Sherman Kenneth E Composition and method of treating hepatitis b
AU751199B2 (en) * 1992-07-13 2002-08-08 Government Of The United States Of America As Represented By The Secretary Of The Army Composition and method of treating hepatitis B
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
TW249754B (esLanguage) * 1993-10-26 1995-06-21 Alpha I Biomedicals Inc
DK0731710T3 (da) * 1993-11-05 2003-06-16 Sciclone Pharmaceuticals Inc Fremgangsmåde og præparat til behandling af patienter med inkompenseret leversygdom
JP3837769B2 (ja) * 1995-06-12 2006-10-25 大塚製薬株式会社 抗ウイルス剤
DK0886527T3 (da) * 1996-02-28 2002-03-04 Unihart Corp Farmaceutiske sammensætninger indeholdende naturligt humant alfa-interferon
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
IL153020A0 (en) 2000-05-26 2003-06-24 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
WO2002011749A1 (en) * 2000-08-07 2002-02-14 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis c with thymosin, interferon and ribavirin
WO2002044717A1 (en) * 2000-12-01 2002-06-06 Cornell Research Foundation Animal model for flaviviridae infection
RU2211703C2 (ru) * 2001-06-08 2003-09-10 ООО НТЦ "Юпитер-2" Антистрессорное и ноотропное средство с антивирусным и иммуностимулирующим действием
AU2002330154A1 (en) * 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
PL371683A1 (en) * 2001-10-05 2005-06-27 Intermune, Inc. Methods of treating liver fibrosis and hepatitis c virus infection
IL161603A0 (en) * 2001-10-26 2004-09-27 Rhode Island Hospital Thymosin augmentation of genetic immunization
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
JP2005522443A (ja) * 2002-02-14 2005-07-28 フアーマセツト・リミテツド 改変フッ素化ヌクレオシド類似体
MY140819A (en) 2002-06-28 2010-01-29 Idenix Caymans Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
BR0312278A (pt) 2002-06-28 2007-06-19 Idenix Cayman Ltd éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
BR0316363A (pt) 2002-11-15 2005-10-04 Idenix Cayman Ltd Nucleosìdeos 2'-ramificado e mutação de flaviviridae
EP2319853B1 (en) 2002-12-12 2014-03-12 IDENIX Pharmaceuticals, Inc. Process for the production of 2'-branched nucleosides
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
JP4149296B2 (ja) * 2003-03-26 2008-09-10 株式会社ルネサステクノロジ 半導体記憶装置
PT1613340E (pt) * 2003-03-28 2010-08-19 Sciclone Pharmaceuticals Inc Tratamento de infecções por aspergillus com timosina alfa 1
EA008037B1 (ru) * 2003-03-28 2007-02-27 Сциклон Фармасьютикалс, Инк. ЛЕЧЕНИЕ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ГРИБАМИ p. ASPERGILLUS, С ПОМОЩЬЮ ТИМОЗИНА АЛЬФА 1
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
PL3521297T3 (pl) 2003-05-30 2022-04-04 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydów
BRPI0412849A (pt) * 2003-07-25 2006-09-26 Idenix Cayman Ltd compostos, composições e usos de análogos de nucleosìdeo de purina para o tratamento de flaviviridae, incluindo hepatite c
WO2005021007A1 (fr) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention et traitement de l'hepatite virale b
WO2005107742A1 (en) 2004-05-05 2005-11-17 Yale University Novel antiviral helioxanthin analogs
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
PT3109244T (pt) 2004-09-14 2019-06-04 Gilead Pharmasset Llc ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
CA2634749C (en) 2005-12-23 2014-08-19 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
CN101437535B (zh) * 2006-05-02 2013-01-30 希格马托制药工业公司 胸腺素α1单独地或与PTX3或更昔洛韦联合在治疗巨细胞病毒感染中的用途
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010042697A1 (en) * 2008-10-08 2010-04-15 University Of Miami Regulation of lymphocytes and uses therefor
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
NZ617066A (en) 2008-12-23 2015-02-27 Gilead Pharmasset Llc Nucleoside analogs
EP2427213B1 (en) 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
ES2644990T3 (es) 2010-03-31 2017-12-01 Gilead Pharmasset Llc Síntesis estereoselectiva de principios activos que contienen fósforo
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) * 2012-11-09 2015-10-21 长春海悦药业有限公司 一种含有胸腺法新的药物组合物及其制剂
NZ716840A (en) 2013-08-27 2017-06-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (esLanguage) * 1991-09-13 1994-05-21 Paul B Chretien

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007132037A1 (es) * 2006-05-10 2007-11-22 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas
ES2288118A1 (es) * 2006-05-10 2007-12-16 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.

Also Published As

Publication number Publication date
JPH06510998A (ja) 1994-12-08
NO941310D0 (no) 1994-04-12
TW224053B (esLanguage) 1994-05-21
WO1993005806A1 (en) 1993-04-01
ZA926964B (en) 1993-04-26
FI941133A0 (fi) 1994-03-10
HUT75166A (en) 1997-04-28
CA2119006A1 (en) 1993-04-01
CZ55194A3 (en) 1994-10-19
CA2119006C (en) 2005-08-23
FI941133L (fi) 1994-03-10
AU667327B2 (en) 1996-03-21
RO111991B1 (ro) 1997-04-30
MX9205240A (es) 1993-07-01
RU94022480A (ru) 1996-07-20
DE69219782T2 (de) 1997-10-09
SG64897A1 (en) 1999-05-25
HK1021687A1 (en) 2000-06-23
CZ286827B6 (cs) 2000-07-12
DK0603305T3 (da) 1997-09-01
AU2644792A (en) 1993-04-27
GR3024025T3 (en) 1997-10-31
DE69219782D1 (de) 1997-06-19
JP3228512B2 (ja) 2001-11-12
RU2104010C1 (ru) 1998-02-10
NO941310L (no) 1994-04-12
FI107879B (fi) 2001-10-31
HU9400758D0 (en) 1994-06-28
US20070218033A1 (en) 2007-09-20
HU221006B1 (hu) 2002-07-29
EP0603305A1 (en) 1994-06-29
US6001799A (en) 1999-12-14
EP0603305B1 (en) 1997-05-14
US5849696A (en) 1998-12-15
ATE152914T1 (de) 1997-05-15
KR100254082B1 (ko) 2000-09-01

Similar Documents

Publication Publication Date Title
ES2103966T3 (es) Uso de una timosina en el tratamiento de hepatitis c.
ES2139574T3 (es) Nuevos gases propulsores y su uso en preparaciones medicas.
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2186714T3 (es) Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado.
NO994091L (no) Medisinsk preparat inneholdende en lipofilisk inertgass
ES2186667T3 (es) Analogos de nucleosidos de 1,3-oxatiolano.
ES2143558T3 (es) Agentes policiclicos antiparasitarios, procedimiento y cepa para su preparacion y su uso.
ES2098029T3 (es) Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
ES2182837T3 (es) Piran-2-onas y 5,6-dihidropiran-2-onas utiles en el tratamiento del sida y de otros retrovirus.
MX17808A (es) Nuevos derivados de artemisinina,procedimiento para su preparacion y su uso como agentes antiprosoos
BR9907882A (pt) Uso de compostos de 1,5-didesóxi-1,5-imino-d-glucitol n-substituìdos para o tratamento de infecções de vìrus de hepatite
ES2134197T3 (es) Vacunas contra el virus del herpes simplex vp16.
ES2108969T3 (es) Utilizacion de analogos de didesoxinucleosidos en el tratamiento de infecciones virales.
MX9706957A (es) Composicion que contiene amlodipina, o una sal, o felodipina y un inhibidor de enzima convertidora de angiotensina.
ES2185655T3 (es) Fracciones de acido aurintricarboxilico y analogos con actividad anti-angiogenica y metodos de uso.
MX9304209A (es) Composicion y metodo de tratamiento de hepatitis b.
ES2131122T3 (es) Uso de il-10 para prevenir la diabetes mellitus dependiente de insulina.
MX9302378A (es) Antagonistas de serotonina.
ES2100689T3 (es) Asociacion sinergizante que tiene un efecto antagonista de los receptores nk1 y nk2.
ES2120962T3 (es) Composicion antivirica.
NO890046L (no) Disubstituerte pyridiner.
ES2123499T3 (es) Metodos y composiciones para tratamiento de infecciones virales.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 603305

Country of ref document: ES